1. Home
  2. Knowledge Base
  3. Medical
  4. Prescribing
  5. Cyproterone and Young People: A Lack of Safety Information

Cyproterone and Young People: A Lack of Safety Information

Cyproterone acetate (CPA) is a medication often used in gender-affirming care and to manage conditions related to excess androgens. However, it’s important to note that cyproterone is not licensed for use in young people under a certain age.

Cyproterone acetate is not licensed for use in young people due to the lack of safety and efficacy information specific to this age group. Healthcare providers prioritise the wellbeing, informed decision-making, and health of their young patients. They often explore alternative approaches that offer flexibility, reversibility, and safety while respecting individual choices and identities. Ultimately, the decision to use CPA or other gender-affirming medications should be made collaboratively, with a focus on ensuring the best possible outcomes for young individuals while acknowledging the need for more research in this area.

Updated on January 20, 2024

Was this article helpful?

Related Articles

Request an article
If you would like some knowledge added to our knowledge base, send your suggestions here.
Request Knowledge